Prostate cancer immunotherapy works better for African-American men – News from Tulane
News from Tulane |
Prostate cancer immunotherapy works better for African-American men
News from Tulane African-American men treated with immunotherapy drug sipuleucel-T had a median nine-month overall survival advantage compared to Caucasian men with the disease, according to an analysis of 1,900 patients who received the treatment between 2011 … Sipuleucil-T Survival Benefit Greater in Blacks |
